Prognostic significance of p16INK4a hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3729-3732

  Ota, Naohiro ^a   Kawakami, Kazuyuki ^a   Okuda, Toshiyuki ^a   Takehara, Akira ^a   Hiranuma, Chikashi ^a   Oyama, Kaeko ^a   Ota, Yasuhiko ^a   Oda, Makoto ^a   Watanabe, Go ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypermethylation; Non small cell lung cancer; p16INK4a; Prognostic factor

Indexed keywords

FORMALDEHYDE; PARAFFIN; PROTEIN P16INK4A;

AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DEMOGRAPHY; DNA METHYLATION; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS;

EID: 33750724417     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
2. Brabender J, Usadel H, Danenberg KD, Metzger R, Schneider PM, Lord RV, Wickramasinghe K, Lum CE, Park J, Salonga D, Singer J, Sidransky D, Holscher AH, Meltzer SJ and Danenberg PV: Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20: 3528-3532, 2001.
3. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK and Mao L: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92: 1511-1516, 2000.
4. Maruyama R, Sugio K, Yoshino I, Maehara Y and Gazdar AF: Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 100: 1472-1477, 2004.
5. Brabender J, Usadel H, Metzger R, Schneider PM, Park J, Salonga D, Tsao-Wei DD, Groshen S, Lord RV, Takebe N, Schneider S, Holscher AH, Danenberg KD and Danenberg PV: Quantitative o(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res 9: 223-227, 2003.
6. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686-692, 1995.
7. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995.
8. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T, Shimizu N and Gazdar AF: The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91: 771-774, 2004.
9. INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 10: 6119-6125, 2004.
10. Kim YT, Park SJ, Lee SH, Kang HJ, Hahn S, Kang CH, Sung SW and Kim JH: Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 130: 1378. Epub Oct 13, 2005.
11. Kim YT, Lee SH, Sung SW and Kim JH: Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 79: 1180-1188, 2005.
12. Safar AM, Spencer H, 3rd, Su X, Coffey M, Cooney CA, Ratnasinghe LD, Hutchins LF and Fan CY: Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 11: 4400-4405, 2005.
13. Tanaka R, Wang D, Morishita Y, Inadome Y, Minami Y, Iijima T, Fukai S, Goya T and Noguchi M: Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer 103: 608-615, 2005.
14. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner G, Weisenberger DJ, Campan M, Laird PW, Loda M and Fuchs CS: CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies. Gut 11: in press, 2006.
15. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32, 2000.
16. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA and Laird PW: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61: 3410-3418, 2001.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.